Kyverna Therapeutics, Inc. (KYTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
NEW ORLEANS, LA / ACCESSWIRE / January 6, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NasdaqGS:KYTX), if they purchased the Company's shares pursuant and/or traceable to the Company's registration statement issued in connection with its February 2024 initial public offering ("IPO").
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc. (KYTX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
KYTX Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Kyverna Therapeutics, Inc. Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
RADNOR, PA / ACCESSWIRE / January 6, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ:KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.
KYTX LAWSUIT ALERT: Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - KYTX
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Kyverna Therapeutics Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO").
